Second-Generation Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep...

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Second-generation tyrosine kinase inhibitors (2G-TKIs), such as dasatinib and nilotinib, offer faster and deeper responses in newly diagnosed chronic phase-chronic myeloid leukemia (CP-CML) compared to imatinib.
• Recent studies have explored the discontinuation of 2G-TKIs in patients who have achieved a stable deep molecular response (DMR).

Purpose of the Study:

• To assess the treatment-free remission (TFR) rate following 2G-TKI discontinuation in CML patients with stable DMR.
• To evaluate the long-term safety of discontinuing 2G-TKIs in this patient population.

Main Methods:

• A meta-analysis was conducted, pooling data from 5 single-armed, prospective cohort studies.
• A total of 517 patients with chronic myeloid leukemia (CML) and stable deep molecular response (DMR) were included.
• Follow-up assessments were performed at 12 and 24 months post-discontinuation.

Main Results:

• The overall weighted mean TFR rate at 12 months was 57% (95% CI 51-64%), and at 24 months was 53% (95% CI 47-60%).
• Loss of TFR was predominantly observed within the first 12 months after discontinuation.
• In patients who restarted TKI therapy after molecular relapse, 96.5% rapidly achieved major molecular response (MMR). Four deaths occurred within the two-year follow-up period.

Conclusions:

• Discontinuation of 2G-TKIs is a feasible strategy for CML patients maintaining a stable DMR.
• The majority of patients who relapse can re-achieve MMR with prompt re-initiation of 2G-TKI therapy.
• Long-term safety appears favorable, with minimal deaths attributed to adverse events and a substantial proportion of patients maintaining TFR.